PDE4 inhibitors
- Increase intracellular cAMP by blocking PDE4
- Roflumilast: COPD exacerbation reduction
- Apremilast: psoriasis/PsA/Behçet
- Topical roflumilast: psoriasis/seb derm
- Diarrhea + weight loss are common systemic AEs
- Neuropsychiatric effects require awareness
- Uses differ markedly by formulation
Class at a glance
- Increase intracellular cAMP by blocking PDE4
Members / distinctions
- Roflumilast: COPD exacerbation reduction
- Apremilast: psoriasis/PsA/Behçet
Clinical role
- Topical roflumilast: psoriasis/seb derm
- Neuropsychiatric effects require awareness
- Uses differ markedly by formulation
Practical pearls
- Diarrhea + weight loss are common systemic AEs
Self-check
- What key adverse effect/risk occurs with PDE4 inhibitors?
Diarrhea + weight loss are common systemic AEs.
Drugs in this class (3)
All drug classes · Open the interactive console ↗
